Studies have shown that VEGFA can affect the infiltration of CD163+ TAM in bladder cancer (22), and the changes in VEGF receptor expression are linked to the disease staging and recurrence of bladder cancer (23). This evidence concerns the gene CD163 and urinary bladder carcinoma.